COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Brownlee, Wallace J

Brownlee, Wallace J.

Brownlee WJ; Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, UK/National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Mult Scler ; 26(10): 1267, 2020 09.

Article in English | MEDLINE | ID: covidwho-695369

Subject(s)

Coronavirus Infections; Lymphopenia; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Betacoronavirus; COVID-19; Cladribine; Humans; SARS-CoV-2

Keywords

COVID-19; multiple sclerosis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Pandemics / Lymphopenia / Multiple Sclerosis Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2020 Document Type: Article Affiliation country: 1352458520948211

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google